Indolent Systemic Mastocytosis Clinical Trials in Catania
2 recruitingCatania, Italy
Showing 1–2 of 2 trials
Recruiting
Phase 2Phase 3
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Indolent Systemic MastocytosisSmoldering Systemic Mastocytosis
Blueprint Medicines Corporation534 enrolled64 locationsNCT04910685
Recruiting
Phase 2
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
MyelofibrosisIndolent Systemic Mastocytosis
Telios Pharma, Inc.121 enrolled52 locationsNCT04655118